1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Validation of patient-reported outcomes in patients with nonmetastatic breast cancer receiving comprehensive nodal irradiation in the RadComp trial
    Journal Article

    Hahn, E. A.; Pugh, S. L.; Lu, H. L.; Vela, A. M.; Gillespie, E. F.; Nichols, E. M.; Wright, J. L.; MacDonald, S. M.; Cahlon, O.; Baas, C.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
    Editorial

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
    Journal Article

    Yamashita, T.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Xu, B.; Wang, X.; Im, S. A.; more...
    Breast Cancer (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase III HIMALAYA study of Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Journal Article

    Sangro, B.; Galle, P. R.; Kelley, R. K.; Charoentum, C.; De Toni, E. N.; Ostapenko, Y.; Heo, J.; Cheng, A. L.; Wilson Woods, A.; Gupta, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of osimertinib in patients with epidermal growth factor receptor mutations: Results from the NCI-MATCH ECOG-ACRIN (EAY131) trial subprotocol E
    Journal Article

    Chen, M. F.; Song, Z.; Yu, H. A.; Sequist, L. V.; Lovly, C. M.; Mitchell, E. P.; Moscow, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Journal Article

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    HemaSphere (2024)

    Fulltext@MSK | Save
  • A randomized, multi-center, open label study to compare the safety and efficacy between afatinib monotherapy and combination therapy with HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
    Journal Article

    Kwag, E.; Kim, S. D.; Shin, S. H.; Oak, C.; Park, S. J.; Choi, J. Y.; Hoon Yoon, S.; Kang, I. C.; Jeong, M. K.; Woo Lee, H.; more...
    Integrative Cancer Therapies (2024)

    Fulltext@MSK | Save